Innovative Neurotechnology Cognision's FDA-cleared COGNISION® System offers a cutting-edge, cloud-powered EEG/ERP solution for neurocognitive assessments, positioning the company as a leader in precision neurobiomarker analysis for clinical and research applications.

Growing Clinical Adoption The system's successful deployment in multiple clinical trials and its launch at prominent events like the AAIC demonstrate strong market acceptance and potential expansion opportunities within neurology and neuropsychology clinics treating dementia, concussion, and neurocognitive disorders.

Research and Collaboration As a founding member of the EEG/ERP Biomarker Qualification Consortium, Cognision is strategically positioned to leverage collaborative partnerships and stay ahead of regulatory and scientific developments, opening avenues for joint ventures and research grants.

Funding and Market Potential With recent funding of $2M and revenues estimated between $1M and $10M, Cognision has the financial backing to scale marketing efforts and expand product outreach to neuroscience research institutions, pharmaceutical companies, and clinical diagnostic labs.

Technology Integration The company's integration of diverse tech tools and cloud-based platforms offers a scalable, user-friendly solution that can be tailored for various clinical and research settings, presenting opportunities to partner with electronic health record providers and medical device distributors.